Market capitalization | $223.74m |
Enterprise Value | $-20.37m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 8.21 |
P/B ratio (TTM) P/B ratio | 0.99 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-2.26m |
Free cash flow (TTM) Free cash flow | $-2.48m |
Cash position | $244.11m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Merrimack Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Merrimack Pharmaceuticals, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | - - |
-
|
|
EBITDA | -2.26 -2.26 |
4%
4%
|
EBIT (operating result) EBIT | -2.26 -2.26 |
3%
3%
|
Net profit | -25 -25 |
1,361%
1,361%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Gary Crocker |
Founded | 1993 |
Website | www.merrimackpharma.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.